The Philadelphia area has given birth to more than 100 biotechnology and specialty pharmaceutical companies with help from the region's healthy supply of research institutions, academic medical centers and drug manufacturers. Lately, the region has started to see an uptick in biopharmaceuticals companies relocating to the region to take advantage of its talent pool complete with scientific researchers, business executives and entrepreneurs with experience developing new drug candidates.
Take the story of Marinus Pharmaceuticals, a biophamraceutical company developing new treatments for epilepsy and other neuropsychiatric disorders. It recently relocated to Radnor, Pa., from Connecticut.
The market for epilepsy treatments is estimated at more than $14 billion. Marinus is initially targeting a $4 billion subset of that market: patients with seizures who don't respond or are no longer responding to other medications in the market.
Read the rest of the story here.
For more business news, check out PBJ.com
